KR20020056612A - The method for production of egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually and egg, yolk, IgY thereof and ice-cream containing complexing specific IgY for anti-Streptococcus mutans, anti-Streptococcus sanguis and anti-Actinomyces israelii - Google Patents
The method for production of egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually and egg, yolk, IgY thereof and ice-cream containing complexing specific IgY for anti-Streptococcus mutans, anti-Streptococcus sanguis and anti-Actinomyces israelii Download PDFInfo
- Publication number
- KR20020056612A KR20020056612A KR1020000086001A KR20000086001A KR20020056612A KR 20020056612 A KR20020056612 A KR 20020056612A KR 1020000086001 A KR1020000086001 A KR 1020000086001A KR 20000086001 A KR20000086001 A KR 20000086001A KR 20020056612 A KR20020056612 A KR 20020056612A
- Authority
- KR
- South Korea
- Prior art keywords
- igy
- egg
- immunoprotein
- streptococcus
- oral disease
- Prior art date
Links
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 235000015243 ice cream Nutrition 0.000 title claims abstract description 15
- 230000000536 complexating effect Effects 0.000 title abstract 2
- 208000025157 Oral disease Diseases 0.000 claims abstract description 30
- 208000030194 mouth disease Diseases 0.000 claims abstract description 30
- 241000186041 Actinomyces israelii Species 0.000 claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 11
- 241000194023 Streptococcus sanguinis Species 0.000 claims abstract description 11
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 3
- 230000000977 initiatory effect Effects 0.000 claims abstract 2
- 102000012214 Immunoproteins Human genes 0.000 claims description 65
- 108010036650 Immunoproteins Proteins 0.000 claims description 65
- 235000013601 eggs Nutrition 0.000 claims description 26
- 102000002322 Egg Proteins Human genes 0.000 claims description 25
- 108010000912 Egg Proteins Proteins 0.000 claims description 25
- 235000013345 egg yolk Nutrition 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 238000011081 inoculation Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 208000002925 dental caries Diseases 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 8
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 230000017448 oviposition Effects 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 description 11
- 235000013330 chicken meat Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 3
- 102000000340 Glucosyltransferases Human genes 0.000 description 3
- 108010055629 Glucosyltransferases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 241000203716 Actinomycetaceae Species 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 241000158496 Corynebacterium matruchotii Species 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000203719 Rothia dentocariosa Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/38—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1292—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Actinomyces; from Streptomyces (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 구강질환을 일으키는 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토코커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii)를 항원화시켜서, 닭에게 각각을 접종하여 산란계의 난황에서 구강질환을 일으키는 균에 대한 특수 면역단백질(IgY)을 생산하여, 각각 생산된 특수 면역단백질을 적정비율로 배합한 복합 특수 면역단백질을 식품첨가제로 이용하는 기술을 제공하는데 그 특징이 있다.The present invention is to inoculate each chicken by inoculating each of the chickens by inoculating Streptococcus mutans , Streptococcus sanguis , Actinomyces israelii causing oral disease, Produces a special immune protein (IgY) against the bacteria causing oral disease in egg yolk, and provides a technology that uses a combination of special immuno-protein combined with a suitable ratio of each produced special immunoprotein as a food additive.
본 발명의 또 다른 특징은 복합 특수 면역단백질을 함유한 아이스크림에 관한 것이다.Another feature of the invention relates to an ice cream containing a complex special immunoprotein.
본 발명과 관련하여 종래 우리나라 기술은 다음의 원리에 따라 발명하였다.In connection with the present invention, the conventional Korean technology was invented according to the following principle.
포유류(태생동물)의 신생아는 모친의 면역항체를 태반 혹은 모유를 통해서 획득하고 자기의 면역 기능이 성숙될 때까지 초기 감염증을 면역시킨다.Newborn babies in mammals obtain their mother's immune antibodies through the placenta or breast milk and immunize early infections until their immune function matures.
그러나, 태반도 모유도 없는 조류 이하의 동물 즉, 난생동물의 경우 어미 닭이 획득한 면역항체는 난황 중에 이행되어 축적되고 자손에 전해진다. 난황 중의 항체는 포유류의 IgG 분류의 항체에 해당되나 단백 화학적 성질이 약간 다르고 또한, 난황 유래의 항체이므로 비교 면역학 분야 등에서는 IgY(Immunoglobulin Yolk)라 부른다.However, in the case of an animal below the placenta and breast milk, that is, an oviparous animal, the immune antibody obtained by the mother chicken is transferred and accumulated in egg yolk and transmitted to the offspring. Antibodies in egg yolk correspond to antibodies of the mammalian IgG class, but have slightly different protein chemistry and are antibodies derived from egg yolk and are therefore called IgY (Immunoglobulin Yolk) in the field of comparative immunology.
어미 닭에서 알을 통해 병아리로 면역항체의 이행은 1893년클렘버러(Klemberer)에 의해 발견되었다.The transfer of immune antibodies from mother chickens to eggs to chicks was discovered in 1893 by Klemberer.
그후 1960년대까지 여러 종류의 항원(세균, 바이러스, 단백질 등)을 산란계에 면역시켜, 대응하는 특이적 항체가 난황 중에 이행, 축적하는 사실이 확인되었다(마키슨 1965; 프라져 등 1934, 펫터슨 등 1962).After that, various kinds of antigens (bacteria, viruses, proteins, etc.) were immunized to laying hens until the 1960s, and it was confirmed that the corresponding specific antibodies migrated and accumulated in egg yolk (Markeyson 1965; Fraser et al. 1934, Petterson). Et al. 1962).
이러한 연구결과를 기초로 우리 나라에서 충치 유발을 예방하기 위해서 닭에 충치 유발균을 접종하여 계란 중 난황에 생성된 면역단백질을 추출하여 구강질환을 예방하는 연구가 실행되어졌다.Based on these findings, a study was conducted to prevent oral diseases by inoculating the caries-causing bacteria in chickens and extracting the immune proteins produced in egg yolk from eggs.
우리 나라에서 이남형(1997)이 면역단백질 함량을 제고시키는 산란계용 사료 및 이 사료에 의해 사양함과 함께 스트랩토코커스 뮤탄스 균주의 백신을 접종시켜 특수 면역단백질을 다량 함유하는 계란을 생산하는 방법(대한민국 공개특허공보 1999-011237)을 출원하였다. 이는 사료에 켈프밀, 또는 계피, 또는 박하, 또는 참숯을 첨가한 배합사료를 산란계에 섭취시킴과 함께 스트랩토코커스 뮤탄스 균주를 산란계에 면역처리하여 면역단백질 함량을 제고시키는 계란생산방법이다. 이승배(1996)가 충치예방용 난황 IgY 항체의 제조 방법(대한민국 공개특허공보 1997-073607)을 출원하였다. 이는 스트랩토코커스 뮤탄스를 산란계에 면역처리하여 충치예방용 난황 IgY 항체 제조방법에 관한 것이다.Lee, Nam-Hyung (1997), in Korea, lays down a diet for raising egg protein and a method for producing eggs containing a large amount of special immunoprotein by inoculating a vaccine of Straptococcus mutans strain as specified by this feed. Korean Patent Application Publication No. 1999-011237). This is an egg production method that ingests feed containing kelp mill, cinnamon, mint or charcoal in the feed to the laying hens, and immunizes the Strain Tococcus mutans to the laying hens to enhance the immunoprotein content. Lee Seung-bae (1996) has applied for a method for preparing egg yolk IgY antibody for caries prevention (Korean Patent Publication No. 1997-073607). This relates to a method for producing egg yolk IgY antibody for preventing caries by immunizing Straptococcus mutans to laying hens.
사람에게서 구강질환을 일으키는 균은 인간 치아 플라그(Human dental plaque)에서 글루칸네이즈(Glucanase)를 생산하는 균으로, 액티노마이세테세에(Actinomycetaceae), 스트랩토코카이(Streptococci), 헤모필리(Haemophili), 그람-음성 혐기성균(Gram-negative anaerobes)으로 크게 나뉘고, 종으로는 스트랩토코커스 상기스(Streptococcus sanguis), 스트랩토코커스 미니터(Streptococcus minitor), 액티노마이세스 네슬렌디(Actinomyces naeslundii), 액티노마이세스 비스코서스(Actinomyces viscosus), 박테리오네마 메트루초티(Bacterionema matruchotii), 박테리오디스 스페이스(Bacteroides species), 로티아 덴토카리오샤(Rothia dentocariosa )등이 있다. The bacteria that cause oral diseases in humans are the bacteria that produce glucanase in human dental plaques, such as Actinomycetaceae, Streptococci, and Haemophili. , Gram-negative anaerobes, which are largely divided into species, Streptococcus sanguis , Streptococcus minitor , Actinomyces naeslundii , Actinomyces viscosus , Bacterionema matruchotii , Bacteroides species , Rothia dentocariosa, and the like .
충치 유발균으로 가장 대표적인 것은 스트랩토코커스 뮤탄스로, 이 균은 설탕 성분 존재시 스트랩토코커스 뮤탄스의 표면 단백질(surface protein)이 치아표면에 결합하여 균 자체에서 생산되는 포도당 전이효소(glucosyl transferase: G Tase)가 충치를 유발하는데 중요한 역할을 한다. 포도당 전이효소(G Tase)가 식사로부터 제공되는 각종 당류를 발효하여 불용성이면서 끈적끈적한 글루칸(glucan)을 생성함으로써 치아 우식증이 시작된다.The most common cause of tooth decay is the straptococcus mutans, which is a glucose transferase (glucosyl transferase) produced by the bacterium itself by binding the surface protein of the straptococcus mutans to the tooth surface in the presence of sugar. G Tase) plays an important role in causing tooth decay. Dental caries is initiated by G Tase fermenting various sugars provided from meals to produce insoluble and sticky glucan.
스트랩토코커스 뮤탄스는 불용성 글루칸을 합성하는 세포결합 포도당 전이효소(Cell Associated Glucosyl Transferase : CA G Tase)와 수용성의 글루칸을 합성하는 무세포 포도당 전이효소(Cell-Free Glucosyl Transferase: CF G Tase)의 2종류 작용으로 치아표면에 결합하여 치아 우식증을 일으킨다.Straptococcus mutans is composed of Cell Associated Glucosyl Transferase (CA G Tase), which synthesizes insoluble glucan, and Cell-Free Glucosyl Transferase (CF G Tase), which synthesizes soluble glucan. Kind action causes the caries to bind to the tooth surface.
그러나, 구강질환은 1가지 균이 아닌 구강질환을 일으키는 다수의 균주를 예방해야 하므로 각각의 특이항체가 함유된 계란에서 면역단백질을 추출하여 혼합한 복합 특수 면역단백질 개발을 필요로 하는 문제점이 있었다.However, oral diseases have a problem in that it is necessary to prevent a number of strains that cause oral diseases, not one bacterium, so that a complex special immunoprotein developed by extracting and mixing immunoproteins from eggs containing each specific antibody.
본 발명의 목적은 상기와 같은 제반 문제점을 해소하기 위해, 종래에는 스트랩토코커스 뮤탄스 균주 하나만으로 항원화하여 면역단백질을 생산하였으나, 본 발명에서는 구강질환을 일으키는 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토코커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii) 균주의 백신을 각각 다른 닭에게 투입해서 이들 3가지 균주에 대한 특수 면역단백질(IgY)의 생산방법을 제공함에 있다.In order to solve the above problems, an object of the present invention is to conventionally produce immunoprotein by antigenizing with only one Straptococcus mutans strain, but in the present invention, Straptococcus mutans (or Streptococcus mutans ) causing oral diseases. , Vaccines of Streptococcus sanguis and Actinomyces israelii strains were injected into different chickens to provide a method for producing specific immunoproteins (IgY) for these three strains. .
본 발명의 또 다른 목적은 각각의 특수 면역단백질을 함유한 계란 생산방법에서 생산된 계란 또는 난황으로부터 추출된 특수 면역단백질을 일정비율 배합하여 제조한 복합 특수 면역단백질을 제조하고, 또한 이 복합 특수 면역단백질을 함유한 아이스크림을 제공함에 있다.It is still another object of the present invention to prepare a complex special immunoprotein prepared by combining a certain proportion of special immunoproteins extracted from eggs or egg yolk produced in the egg production method containing each special immunoprotein, and also the complex special immunity. To provide an ice cream containing protein.
도 1은 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토토커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii)에 대한 특수 면역단백질(IgY) 역가 변화이다.1 is a specific immunoprotein (IgY) titer change for Streptococcus mutans , Streptococcus sanguis , Actinomyces israelii .
도 2는 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토토커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii)에 대한 총 면역단백질(IgY) 역가이다.FIG. 2 shows total immunoprotein (IgY) titers for Streptococcus mutans , Streptococcus sanguis , Actinomyces israelii .
도 3은 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토코커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii)에 대한 특수 면역단백질(IgY) 역가이다.FIG. 3 is a specific immunoprotein (IgY) titer for Streptococcus mutans , Streptococcus sanguis , Actinomyces israelii .
전술한 기술적 과제를 달성하기 위하여, 본 발명은 구강질환을 일으키는 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토코커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii)를 항원화시켜서, 닭에게 각각을 접종하여 산란계의 난황에서 구강질환을 일으키는 균에 대한 특수 면역단백질(IgY)을 생산하여, 각각 생산된 특수 면역단백질을 일정비율로 배합한 복합 특수 면역단백질을 제공하는 방법에 그 특징이 있다.In order to achieve the above technical problem, the present invention is to antigenize Streptococcus mutans ( Streptococcus mutans ), Streptococcus sanguis , Actinomyces israelii causing oral disease Inoculate each chicken to produce a special immunoprotein (IgY) against bacteria causing oral disease in egg yolks of laying hens, and to provide a complex special immunoprotein containing a specific ratio of each produced special immunoprotein. There is a characteristic.
또 다른 발명은 상기 생산방법으로 생산된 항 구강질환 특수 면역단백질(IgY)을 함유한 계란, 난황, 복합 특수 면역단백질을 제공하는데 그 특징이 있다.Another invention is characterized by providing eggs, egg yolk, and complex special immunoproteins containing anti-oral disease special immunoproteins (IgY) produced by the production method.
또 다른 발명은 상기 계란이나 난황으로부터 추출한 항 구강질환 복합 특수면역단백질을 함유한 아이스크림에 관한 것이다.Another invention relates to an ice cream containing an anti-oral disease complex special immune protein extracted from the egg or egg yolk.
본 발명의 구성을 보다 상세하게 기술하면, 닭에게 스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리 항원 각각을 유화제 수산화나트륨과 혼합하여 1차 접종하고, 유화제(ISA25)와 혼합하여 2차 접종 후, 균질화하여 산란 개시 후 총 9회를 접종하며, 접종간격은 2주 정도로 투여량이 균수 108/㎖ 정도가 되게 접종 면역 처리하여 난황에 3가지 항원에 대한 특수 면역단백질을 함유하는 것을 특징으로 하는 계란 생산방법에 관한 것이다.In more detail, the composition of the present invention is first inoculated to chickens by mixing each of the Straptococcus mutans, the Straptococcus lance, and the Actinomyces israeli antigen with an emulsifier sodium hydroxide, and the emulsifier (ISA25) and After the second inoculation by mixing, homogenization is performed to inoculate a total of nine times after the start of spawning, and the inoculation interval is immunized with a dose of about 10 8 / ml for about 2 weeks to immunize special yolk proteins for three antigens in egg yolk. It relates to an egg production method characterized in that it contains.
상기 발명을 보다 구체적으로 기술하면, 닭에 투여된 항원에 대해 획득한 특수 면역단백질을 함유한 계란을 소정의 용기를 이용하여 난황막을 분리한 난황을 추출하고, 추출된 난황에 증류수를 첨가하고 교반 후, 저온 방에서 일정시간 방치 후, 원심 분리한 상등액에 함유된 수용성 특수 면역단백질인 스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리 항원에 대한 각각의 특수 면역단백질 비를 1 : 1 : 1 또는 1 : 2 : 2로 배합한 것을 특징으로 한다.In more detail, the egg yolk obtained by separating the egg yolk membrane from the egg containing the special immunoprotein obtained for the antigen administered to the chicken using a predetermined container is extracted, and distilled water is added to the extracted egg yolk and stirred. After a certain period of time in a low temperature room, the ratios of the specific immunoproteins to the water-soluble special immunoproteins Straptococcus mutans, Straptococcus lanceus, and Actinomyces israeli antigen contained in the supernatant centrifuged were determined. It is characterized by mix | blending with 1: 1: or 1: 2: 2.
또 다른 발명의 구성은 상기의 특수 면역단백질의 일정 비율 중 어느 하나로 배합한 항 구강질환 복합면역단백질을 첨가한 아이스크림을 제조시, 항 구강질환 복합면역단백질 난황 분말 5.0%이하, 항 구강질환 복합면역단백질 IgY 추출분말 0.6%이하로 첨가한 아이스크림에 관한 것이다.Another aspect of the present invention is to prepare an ice cream containing the anti-oral disease complex immune protein formulated in any one of the specific ratio of the above-mentioned special immuno-protein, anti-oral disease complex immune protein egg yolk powder 5.0% or less, anti-oral disease complex immunity It relates to an ice cream added with less than 0.6% protein IgY extract powder.
이하에서는 본 발명의 구성을 보다 구체적으로 실시예에 의거하여 보다 상세히 설명하기로 하겠다.Hereinafter, the configuration of the present invention will be described in more detail based on examples.
다만, 본 발명의 권리범위는 실시예에 의하여 본 발명의 청구범위가 한정되는 것은 아니다.However, the scope of the present invention is not limited to the claims of the present invention by the embodiment.
실시예 1Example 1
스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리항원 각각을 닭에 접종 및 면역단백질(IgY) 제조Inoculation of chickens with Straptococcus mutans, Straptococcus lanceus, Actinomyces Israeli antigen and production of immunoprotein (IgY)
연세대 한국 미생물 보존센터에서 동결건조된 스트랩토코커스 뮤탄스(KCCM11823), 스트랩토코커스 상기스를 구입하여 사용하였고, 오타커(Otake: 1991)배양법으로 스트랩토코커스 뮤탄스, 스트랩토코커스 상기스 각각을 브레인-하트 인퓨젼(Brain-Heart Infusion: BHI) 배지에서 설탕(sucrose) 5% 첨가하여 37℃에서 스트랩토코커스 뮤탄스는 24시간, 스트랩토코커스 상기스는 48시간 혐기배양하여 증균시키며, 액티노마이세스 이스라엘리는 브레인-하트 인퓨젼 배지에서 3∼7일간 37℃, 10% CO2배양기(incubator)에서 증균시켰다.The lyophilized Straptococcus mutans (KCCM11823) and Straptococcus lance were purchased and used at the Yonsei University Korea Microbial Conservation Center, and the Straptococcus mutans and Straptococcus lance were respectively used in the Otaker (Otake: 1991) culture method. Was added by 5% sucrose in Brain-Heart Infusion (BHI) medium at 37 ° C. at 37 ° C. for 24 hours for Straptococcus mutans, and for 48 hours for Straptococcus lance, and enriched by Actino Meises Israeli was enriched in brain-heart infusion medium at 37 ° C., 10% CO 2 incubator for 3-7 days.
위와 같이 각각 증균된 스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리 균주를 5% 포르말린 용액이 첨가된 배양기(incubator)에서 사멸시킨 후, 사멸된 균 10,000g을 5℃에서 15분간 원심분리하여 수집하였다.After each of the above-expanded Straptococcus mutans, Straptococcus lanceus, Actinomyces israeli strain were killed in an incubator to which 5% formalin solution was added, 10,000 g of the killed bacteria were added at 5 ° C. Collected by centrifugation for 15 minutes.
상기 각각의 3가지 균주를 1차 접종 때는 유화제 수산화알미늄을, 2차부터는 유화제(IAS25)로 혼합 후, 균질화하여 산란 개시 후 총 9회를 접종하며, 접종 간격은 2주 정도로 투여량이 균수 108/㎖ 정도가 되게 접종 면역처리하였다.The emulsifier hydroxide aluminum when the three strains each of said first dose, and then mixed with an emulsifier (IAS25) since the second, homogenized and inoculated with a total of nine times after the start of spawning, immunization interval is viable count dose as 2 weeks 10 8 Immunization was inoculated to about / ml.
실시예 2Example 2
1. 스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리 항원 접종후 총 면역단백질(IgY)함량 및 특수 면역단백질(IgY)함량1. Total immunoprotein (IgY) content and special immunoprotein (IgY) content after inoculation of Straptococcus mutans, Straptococcus lanceus, Actinomyces Israeli antigen
산란계 시험 33주간 동안에 수집된 계란은 1주 단위로 동일 처리구 계란을 혼합 균질화시킨 후에 난황 10g에 증류수 100㎖를 첨가한 후 교반시키고, 4℃ 저온 방에서 12시간 방치하였다. 10,000×g에서 15분간 원심분리하여 수용성 특수 면역단백질을 분리하였다.Eggs collected during the 33 weeks of laying hens were mixed and homogenized with the same treatment eggs on a weekly basis, and then, after adding 100 ml of distilled water to 10 g of egg yolk, the mixture was stirred and left for 4 hours in a low temperature room at 4 ° C. Water-soluble special immunoproteins were isolated by centrifugation at 10,000 × g for 15 minutes.
분리한 특수 면역단백질 함량을 분석한 자료는 표 1에 나타내었다.The data for analyzing the content of isolated special immunoprotein is shown in Table 1.
대조구보다 복합 균주구의 특수 면역단백질(IgY)의 함량이 많았으며, 스트랩토코커스 뮤탄스 균주의 특수 면역단백질 함량이 가장 많았고, 스트랩토코커스 상기스 균주와 액티노마이세스 이스라엘리 균주의 특수 면역단백질의 함량은 유사하게 나타났다.The specific immunoprotein (IgY) content of complex strains was higher than that of control, and the specific immunoprotein contents of Straptococcus mutans strains were the highest, and the specific immunoproteins of Straptococcus strains and Actinomyces israeli strains. The content of appeared similar.
2. 총 면역단백질(IgY) 및 특수 면역단백질(IgY) 역가 측정2. Determination of total immunoprotein (IgY) and special immunoprotein (IgY) titers
총 면역단백질(IgY) 및 특수 면역단백질(IgY) 역가는 모두 비경쟁적 샌드위치 엘리사 테스트(non-competitive sandwich ELISA test)로 측정하며, 특수 면역단백질(IgY) 역가는 스트랩토코커스 뮤탄스를 함유한 코팅버퍼(0.02M Tris, 0.15 NaCl, pH 9.0)를 준비하고, 마이크로플레이트 웰(microplate well)에 100㎕를 채우고, 4℃에서, 12시간 배양하였다.The total immunoprotein (IgY) and special immunoprotein (IgY) titers are all measured by a non-competitive sandwich ELISA test, and the special immunoprotein (IgY) titers are coatings containing Straptococcus mutans. Buffer (0.02M Tris, 0.15 NaCl, pH 9.0) was prepared, 100 μl was filled in a microplate well, and incubated at 4 ° C. for 12 hours.
수세 버퍼(washing buffer; 0.02M Tris, 0.15M NaCl, 0.05% Tween 20, pH 7.4) 150㎕로 3회 수세시킨 후, 분석할 시료(난황 수용성 면역단백질) 100㎕를 첨가하고 실온에서 1시간 반응시켰다가 다시 수세 버퍼 150㎕로 3회 수세시키고, 10,000 : 1로 희석된 토끼 항-닭 IgG Ab-HRB 100㎕를 첨가하여 실온에서 1시간 반응시킨 후, 다시 수세 버퍼 150㎕로 3회 수세시키고, 기질용액(0.1% TM BS, 0.05M 구연산-인산 버퍼, pH 5.0, 0.02% H2O2) 100㎕ 첨가하였다.After washing three times with 150 µl of washing buffer (0.02 M Tris, 0.15 M NaCl, 0.05% Tween 20, pH 7.4), 100 µl of the sample to be analyzed (yolk soluble immunoprotein) was added and reacted at room temperature for 1 hour. After washing three times with 150 μl wash buffer, 100 μl of rabbit anti-chicken IgG Ab-HRB diluted to 10,000: 1 was added and reacted at room temperature for 1 hour, followed by washing three times with 150 μl wash buffer. , 100 μl of substrate solution (0.1% TM BS, 0.05M citric acid-phosphate buffer, pH 5.0, 0.02% H 2 O 2 ) was added.
실온에서 1시간 반응시키고 반응정지액(2N H2SO4) 50㎕를 가하여 450㎚에서 흡광도(O.D)를 측정하였다.The mixture was reacted at room temperature for 1 hour, and 50 µl of a reaction stopper solution (2N H 2 SO 4 ) was added thereto, and the absorbance (OD) was measured at 450 nm.
산란계 시험 33주 동안에 수집된 계란의 난황에서 얻어진 특수 면역단백질의 역가의 변화량을 도 1에 나타내었다.The change in titer of the specific immunoprotein obtained in egg yolk collected during 33 weeks of laying hens is shown in FIG. 1.
측정된 결과는, 총 면역단백질 역가는 도 2 및 특수 면역단백질(IgY)은 도 3에 제시된 바와 같다.The measured results are as shown in the total immunoprotein titers in FIG. 2 and the specific immunoproteins (IgY) in FIG. 3.
도 2를 참조하여 총 면역단백질 역가를 설명하면, 스트랩토코커스 뮤탄스 균주에 대한 역가가 가장 높게 측정되고, 스트랩토코커스 상기스와 액티노마이세스 이스라엘리 균주의 역가는 스트랩토코커스 뮤탄스 균주보다 낮았지만, 유사하였다. 일반 계란에 해당하는 대조구의 총 면역단백질 역가는 170에 가깝게 측정되었고 구강 질환 예방에 필요한 특수 면역단백질 역가는 170보다 높게 측정되었다.Referring to Figure 2, when describing the total immunoprotein titers, the titers for the Straptococcus mutans strain is measured the highest, and the titers of the Straptococcus above and Actinomyces israeli strain than the Straptococcus mutans strain Low, but similar. The total immunoprotein titer of the control group corresponding to the normal egg was measured close to 170, and the specific immunoprotein titer necessary for the prevention of oral disease was higher than 170.
도 3을 참조하여 특수 면역단백질의 역가를 설명하면, 스트랩토코커스 뮤탄스의 역가는 1.2, 스트랩토코커스 상기스는 0.5, 액티노마이세스 이스라엘리는 0.55로 측정되었다. 대조구인 일반 계란에서는 거의 측정되지 않았다.Referring to FIG. 3, the titer of the specific immunoprotein was determined to be 1.2, Straptococcus mutans 0.5, and Actinomyces Israeli 0.55. It was rarely measured in the control egg.
이 실험에서 스트랩토코커스 뮤탄스 균주에 대한 면역단백질이 가장 많이 만들어졌고, 다른 균주에 대한 면역단백질은 적게 만들어졌다.In this experiment, the most immunoproteins for the Straptococcus mutans strain were made, while the other were less.
실시예 3Example 3
추출된 스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리 항원에 대한 면역단백질을 혼합하는 배합공정Blending process for mixing immunosuppressive protein against extracted Straptococcus mutans, Straptococcus lanceus, Actinomyces israeli antigen
스트랩토코커스 뮤탄스, 스트랩토코커스 상기스, 액티노마이세스 이스라엘리에 대한 면역단백질을 1 : 1 : 1 또는 1 : 2 : 2로 배합한 복합면역단백질을 생산하였다.A complex immune protein was prepared in which an immunoprotein against Straptococcus mutans, Straptococcus lanceus, Actinomyces israeli was combined at 1: 1: 1 or 1: 2: 2.
실시예 4Example 4
복합 특수 면역단백질 첨가 아이스크림 제조Manufacture of complex special immunoprotein-added ice cream
항-구강질환 복합 면역단백질 난황 분말 5.0%, 항-구강질환 복합 면역단백질추출분말 0.6%를 함유하는 아이스크림 제조 배합비를 표 2에 예시하였다.The preparation ratio of ice cream containing 5.0% of anti-oral disease complex immunoprotein yolk powder and 0.6% of anti-oral disease complex immunoprotein extract powder is shown in Table 2.
본 발명은 상술한 특정의 실시예, 도표나 도면에 기재된 내용에 기술적 사상이 한정되지 아니하며, 청구범위에서 청구하는 본 발명의 요지를 벗어남이 없이 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면 누구든지 다양한 변형의 실시가 가능한 것은 물론이고, 그와 같은 변경은 청구범위 기재의 범위 내에 있게 된다.The present invention is not limited to the technical spirit described in the specific embodiments, diagrams or drawings described above, and those skilled in the art without departing from the gist of the invention claimed in the claims. As long as anyone can carry out various modifications, such changes are within the scope of the claims.
본 발명에 의해 생산된 스트랩토코커스 뮤탄스(Streptococcus mutans), 스트랩토코커스 상기스(Streptococcus sanguis), 액티노마이세스 이스라엘리(Actinomyces israelii) 항원에 대한 각각의 특수 면역단백질(IgY)을 배합한 복합 특수 면역단백질을 함유한 계란 및 이 계란으로부터 추출한 복합 특수 면역단백질을 함유한 아이스크림 등을 섭취하게 함으로써 구강질환 예방에 탁월한 효능을 발휘할 수 있게 되었다. Combined with each specific immunoprotein (IgY) against the Streptococcus mutans , Streptococcus sanguis , Actinomyces israelii antigen produced by the present invention Eggs containing complex special immunoproteins and ice creams containing complex special immunoproteins extracted from these eggs can be ingested to provide excellent efficacy in preventing oral diseases.
또한, 본 발명에 의한 생산방법에 의하여 생산된 계란의 난황에서 추출된 복합 특수 면역단백질은 수용성이므로 물에 타서 쉽게 구강을 청소할 수 있는 특징이 있고, 설탕함량이 높은 과자류나 아이스크림 등에 구강질환 특수 면역단백질을 첨가함으로써, 치아 우식, 잇몸병 등에 대한 기대효과가 예상된다.In addition, the complex special immunoprotein extracted from egg yolk of the egg produced by the production method according to the present invention is water-soluble, so it is easy to clean the mouth by burning in water, has a high sugar content, such as confectionery or ice cream special immunity By adding protein, expected effects on dental caries, gum disease and the like are expected.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000086001A KR20020056612A (en) | 2000-12-29 | 2000-12-29 | The method for production of egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually and egg, yolk, IgY thereof and ice-cream containing complexing specific IgY for anti-Streptococcus mutans, anti-Streptococcus sanguis and anti-Actinomyces israelii |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000086001A KR20020056612A (en) | 2000-12-29 | 2000-12-29 | The method for production of egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually and egg, yolk, IgY thereof and ice-cream containing complexing specific IgY for anti-Streptococcus mutans, anti-Streptococcus sanguis and anti-Actinomyces israelii |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0084136A Division KR100437500B1 (en) | 2003-11-25 | 2003-11-25 | Ice-cream containing the Mixed IgY or Yolk Extracted from Egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020056612A true KR20020056612A (en) | 2002-07-10 |
Family
ID=27689107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000086001A KR20020056612A (en) | 2000-12-29 | 2000-12-29 | The method for production of egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually and egg, yolk, IgY thereof and ice-cream containing complexing specific IgY for anti-Streptococcus mutans, anti-Streptococcus sanguis and anti-Actinomyces israelii |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20020056612A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR850000982A (en) * | 1983-07-25 | 1985-03-14 | 미즈노에 고오에이 | Non-carious antibody for treating caries by human streptococcus mutans and method for producing the composition |
JPH01203317A (en) * | 1988-02-09 | 1989-08-16 | Kanebo Ltd | Antibody and dental caries preventing agent containing said antibody as effective component |
JPH03279398A (en) * | 1990-03-29 | 1991-12-10 | Taiyo Kagaku Co Ltd | Antibody and anticarious composition containing same antibody as active ingredient |
KR960000086A (en) * | 1994-06-20 | 1996-01-25 | 서중일 | Method for producing lactic acid bacteria fermented beverage using eggs |
KR970073607A (en) * | 1996-05-29 | 1997-12-10 | 이승배 | Preparation of egg yolk IgY antibody for caries prevention |
KR19990011237A (en) * | 1997-07-22 | 1999-02-18 | 김태수 | Feeding for laying hens to increase the content of immunoproteins and methods for producing eggs containing large amounts of specific immune proteins by inoculation with the vaccine of the Strain Tococcus mutans strain |
KR20020021545A (en) * | 2000-09-15 | 2002-03-21 | 이은선 | FERMENTED MILK, MILK, ICECREAM USING EGG YOLK HAVING IgY, AND ITS METHOD FOR PREPARING |
-
2000
- 2000-12-29 KR KR1020000086001A patent/KR20020056612A/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR850000982A (en) * | 1983-07-25 | 1985-03-14 | 미즈노에 고오에이 | Non-carious antibody for treating caries by human streptococcus mutans and method for producing the composition |
JPH01203317A (en) * | 1988-02-09 | 1989-08-16 | Kanebo Ltd | Antibody and dental caries preventing agent containing said antibody as effective component |
JPH03279398A (en) * | 1990-03-29 | 1991-12-10 | Taiyo Kagaku Co Ltd | Antibody and anticarious composition containing same antibody as active ingredient |
KR960000086A (en) * | 1994-06-20 | 1996-01-25 | 서중일 | Method for producing lactic acid bacteria fermented beverage using eggs |
KR970073607A (en) * | 1996-05-29 | 1997-12-10 | 이승배 | Preparation of egg yolk IgY antibody for caries prevention |
KR19990011237A (en) * | 1997-07-22 | 1999-02-18 | 김태수 | Feeding for laying hens to increase the content of immunoproteins and methods for producing eggs containing large amounts of specific immune proteins by inoculation with the vaccine of the Strain Tococcus mutans strain |
KR20020021545A (en) * | 2000-09-15 | 2002-03-21 | 이은선 | FERMENTED MILK, MILK, ICECREAM USING EGG YOLK HAVING IgY, AND ITS METHOD FOR PREPARING |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4324782A (en) | Dental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells | |
US8637025B2 (en) | Composition and method for the treatment and prevention of enteric bacterial infections | |
Michalek et al. | Effective immunity to dental caries: dose-dependent studies of secretory immunity by oral administration of Streptococcus mutans to rats | |
CA1219806A (en) | Production of antibodies | |
Shimazaki et al. | Passive immunization with milk produced from an immunized cow prevents oral recolonization by Streptococcus mutans | |
KR100446856B1 (en) | anti pityrosporum ovale IgY and its uses | |
KR100437500B1 (en) | Ice-cream containing the Mixed IgY or Yolk Extracted from Egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually | |
KR20020056612A (en) | The method for production of egg containing anti-Streptococcus mutans IgY, anti-Streptococcus sanguis IgY and anti-Actinomyces israelii IgY individually and egg, yolk, IgY thereof and ice-cream containing complexing specific IgY for anti-Streptococcus mutans, anti-Streptococcus sanguis and anti-Actinomyces israelii | |
KR100415911B1 (en) | The method for production of egg containing anti-E.coli IgY and anti-Helicobacter pylori IgY simultaneously, and egg, yogurt and ice-cream containing specific IgY for anti-E.coli and anti-Helicobacter pylori | |
JPH1180197A (en) | Preventive and therapeutic agent against helicobacter pylori and relating infections | |
KR100435829B1 (en) | METHOD FOR PRODUCING IgY AGAINST SUCRASE AND MALTASE AND COMPOSITIONS CONTAINING SAME FOR INHIBITING CARBOHYDRATE UPTAKE | |
JP4982629B2 (en) | Antibody and anti-periodontal disease composition containing antibody | |
KR100422074B1 (en) | The method for production of egg containing anti-E.coli IgY and anti-Helicobacter pylori IgY and anti-Salmonella enteritidis and Salmonella typhimurium simultaneously, and egg, yolk, yogurt and ice-cream containing specific IgY for anti-E.coli and anti-Helicobacter pylori and anti-Salmonella enteritidis and anti-Salmonella typhimurium | |
US20040126384A1 (en) | Combination of IgY against dental caries | |
JP2689511B2 (en) | Food | |
IE76730B1 (en) | Method and product for the treatment of gastric disease | |
KR100286761B1 (en) | Feed for egg-laying hen capable of increasing the content of an immunoprotein and method for eggs containing a large amount of immunoproteins using the same | |
JP2666211B2 (en) | Antibody and method for producing anti-caries agent containing the same as an active ingredient | |
JPH03279398A (en) | Antibody and anticarious composition containing same antibody as active ingredient | |
KR100476502B1 (en) | Anti-Helicobacter pylori antibody and foods containing the same | |
JPH01242534A (en) | Antibody and anticarious agent containing said antibody as active ingredient | |
JPH01226828A (en) | Antibody and caries-preventing agent containing said antibody as active component | |
JPS6315247B2 (en) | ||
Yeung et al. | Efficacy of oral immunization against non-typable Haemophilus influenzae in man | |
PH12015000013A1 (en) | Avian eggs and egg extracts containing igy with glycosidase-inhibitory activities for treatment or prevention of type 2 diabetes mellitus, obesity, metabolic syndrome, overweight condition and for general nutritional or health management in humans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E601 | Decision to refuse application |